Medical Care
Global Gene Modifying Immunotherapy for Blood Cancer Market Insights, Forecast to 2030
- Mar 07, 25
- ID: 1119
- Pages: 89
- Figures: 115
- Views: 1
Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
Market Analysis and Insights: Global Gene Modifying Immunotherapy for Blood Cancer Market
The global Gene Modifying Immunotherapy for Blood Cancer market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Gene Modifying Immunotherapy for Blood Cancer is widely used in various fields, such as Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, B Cell Lymphoma and Multiple Myeloma, etc. Acute Lymphocytic Leukemia provides greatest supports to the Gene Modifying Immunotherapy for Blood Cancer industry development. In 2023, global % revenue of Gene Modifying Immunotherapy for Blood Cancer went into Acute Lymphocytic Leukemia filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Gene Modifying Immunotherapy for Blood Cancer market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Gene Modifying Immunotherapy for Blood Cancer, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Gene Modifying Immunotherapy for Blood Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gene Modifying Immunotherapy for Blood Cancer revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Gene Modifying Immunotherapy for Blood Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Gene Modifying Immunotherapy for Blood Cancer revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
Segment by Type
CAR T-cell Therapy
TCR T-cell Therapy
Segment by Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Gene Modifying Immunotherapy for Blood Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Modifying Immunotherapy for Blood Cancer companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Modifying Immunotherapy for Blood Cancer revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Market Analysis and Insights: Global Gene Modifying Immunotherapy for Blood Cancer Market
The global Gene Modifying Immunotherapy for Blood Cancer market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Gene Modifying Immunotherapy for Blood Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Gene Modifying Immunotherapy for Blood Cancer is widely used in various fields, such as Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, B Cell Lymphoma and Multiple Myeloma, etc. Acute Lymphocytic Leukemia provides greatest supports to the Gene Modifying Immunotherapy for Blood Cancer industry development. In 2023, global % revenue of Gene Modifying Immunotherapy for Blood Cancer went into Acute Lymphocytic Leukemia filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Gene Modifying Immunotherapy for Blood Cancer market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Gene Modifying Immunotherapy for Blood Cancer, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Gene Modifying Immunotherapy for Blood Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gene Modifying Immunotherapy for Blood Cancer revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Gene Modifying Immunotherapy for Blood Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Gene Modifying Immunotherapy for Blood Cancer revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
Segment by Type
CAR T-cell Therapy
TCR T-cell Therapy
Segment by Application
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Gene Modifying Immunotherapy for Blood Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Modifying Immunotherapy for Blood Cancer companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Modifying Immunotherapy for Blood Cancer revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 CAR T-cell Therapy
1.2.3 TCR T-cell Therapy
1.3 Market by Application
1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2019-2030)
2.2 Global Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Region
2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2019-2024)
2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2025-2030)
2.3 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
2.3.1 Gene Modifying Immunotherapy for Blood Cancer Industry Trends
2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Gene Modifying Immunotherapy for Blood Cancer by Players
3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2019-2024)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2023
3.5 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer Head office and Area Served
3.6 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
3.7 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2019-2024)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2025-2030)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2019-2024)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
6.2.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
6.2.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
6.2.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
6.3.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
6.3.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
6.3.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
6.4.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
6.4.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
7.2.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
7.2.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
7.2.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
7.3.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
7.3.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
7.3.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
7.4.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
7.4.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
8.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
8.2.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
8.2.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
8.2.3 China Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
8.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
8.3.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
8.3.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
8.3.3 China Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
9.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
9.2.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
9.2.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
9.2.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
9.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
9.3.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
9.3.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
9.3.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
9.4 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region
9.4.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024)
9.4.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.1.5 Novartis Recent Developments
11.2 Kite Pharma
11.2.1 Kite Pharma Company Details
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.2.5 Kite Pharma Recent Developments
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Details
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.3.5 Juno Therapeutics Recent Developments
11.4 Cellectis
11.4.1 Cellectis Company Details
11.4.2 Cellectis Business Overview
11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.4.5 Cellectis Recent Developments
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.5.5 Ziopharm Oncology Recent Developments
11.6 Celyad
11.6.1 Celyad Company Details
11.6.2 Celyad Business Overview
11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.6.5 Celyad Recent Developments
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Details
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.7.5 Bluebird Bio Recent Developments
11.8 Bellicum Pharmaceuticals
11.8.1 Bellicum Pharmaceuticals Company Details
11.8.2 Bellicum Pharmaceuticals Business Overview
11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.8.5 Bellicum Pharmaceuticals Recent Developments
11.9 Mustang Bio
11.9.1 Mustang Bio Company Details
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.9.5 Mustang Bio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 CAR T-cell Therapy
1.2.3 TCR T-cell Therapy
1.3 Market by Application
1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Acute Lymphocytic Leukemia
1.3.3 Chronic Lymphocytic Leukemia
1.3.4 B Cell Lymphoma
1.3.5 Multiple Myeloma
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2019-2030)
2.2 Global Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Region
2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2019-2024)
2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2025-2030)
2.3 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
2.3.1 Gene Modifying Immunotherapy for Blood Cancer Industry Trends
2.3.2 Gene Modifying Immunotherapy for Blood Cancer Market Drivers
2.3.3 Gene Modifying Immunotherapy for Blood Cancer Market Challenges
2.3.4 Gene Modifying Immunotherapy for Blood Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Gene Modifying Immunotherapy for Blood Cancer by Players
3.1.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2019-2024)
3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
3.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2023
3.5 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer Head office and Area Served
3.6 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
3.7 Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Type
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2019-2024)
4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2025-2030)
5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application
5.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2019-2024)
5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
6.2.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
6.2.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
6.2.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
6.3.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
6.3.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
6.3.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
6.4.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
6.4.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
7.2.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
7.2.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
7.2.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
7.3.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
7.3.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
7.3.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
7.4.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
7.4.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
8.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
8.2.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
8.2.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
8.2.3 China Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
8.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
8.3.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
8.3.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
8.3.3 China Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
9.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
9.2.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
9.2.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
9.2.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
9.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
9.3.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
9.3.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
9.3.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
9.4 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region
9.4.1 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024)
9.4.3 Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.1.5 Novartis Recent Developments
11.2 Kite Pharma
11.2.1 Kite Pharma Company Details
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
11.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.2.5 Kite Pharma Recent Developments
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Details
11.3.2 Juno Therapeutics Business Overview
11.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
11.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.3.5 Juno Therapeutics Recent Developments
11.4 Cellectis
11.4.1 Cellectis Company Details
11.4.2 Cellectis Business Overview
11.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
11.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.4.5 Cellectis Recent Developments
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.5.5 Ziopharm Oncology Recent Developments
11.6 Celyad
11.6.1 Celyad Company Details
11.6.2 Celyad Business Overview
11.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
11.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.6.5 Celyad Recent Developments
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Details
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.7.5 Bluebird Bio Recent Developments
11.8 Bellicum Pharmaceuticals
11.8.1 Bellicum Pharmaceuticals Company Details
11.8.2 Bellicum Pharmaceuticals Business Overview
11.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
11.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.8.5 Bellicum Pharmaceuticals Recent Developments
11.9 Mustang Bio
11.9.1 Mustang Bio Company Details
11.9.2 Mustang Bio Business Overview
11.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
11.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
11.9.5 Mustang Bio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of CAR T-cell Therapy
Table 3. Key Players of TCR T-cell Therapy
Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2019-2024)
Table 8. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2025-2030)
Table 10. Gene Modifying Immunotherapy for Blood Cancer Market Trends
Table 11. Gene Modifying Immunotherapy for Blood Cancer Market Drivers
Table 12. Gene Modifying Immunotherapy for Blood Cancer Market Challenges
Table 13. Gene Modifying Immunotherapy for Blood Cancer Market Restraints
Table 14. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Players (2019-2024)
Table 16. Global Top Gene Modifying Immunotherapy for Blood Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2023)
Table 17. Global Gene Modifying Immunotherapy for Blood Cancer Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Headquarters and Area Served
Table 20. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
Table 21. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2019-2024)
Table 25. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2025-2030)
Table 27. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2019-2024)
Table 29. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2025-2030)
Table 31. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Gene Modifying Immunotherapy for Blood Cancer Product
Table 66. Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 67. Novartis Recent Developments
Table 68. Kite Pharma Company Details
Table 69. Kite Pharma Business Overview
Table 70. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product
Table 71. Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 72. Kite Pharma Recent Developments
Table 73. Juno Therapeutics Company Details
Table 74. Juno Therapeutics Business Overview
Table 75. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product
Table 76. Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 77. Juno Therapeutics Recent Developments
Table 78. Cellectis Company Details
Table 79. Cellectis Business Overview
Table 80. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product
Table 81. Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 82. Cellectis Recent Developments
Table 83. Ziopharm Oncology Company Details
Table 84. Ziopharm Oncology Business Overview
Table 85. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product
Table 86. Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 87. Ziopharm Oncology Recent Developments
Table 88. Celyad Company Details
Table 89. Celyad Business Overview
Table 90. Celyad Gene Modifying Immunotherapy for Blood Cancer Product
Table 91. Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 92. Celyad Recent Developments
Table 93. Bluebird Bio Company Details
Table 94. Bluebird Bio Business Overview
Table 95. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 96. Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 97. Bluebird Bio Recent Developments
Table 98. Bellicum Pharmaceuticals Company Details
Table 99. Bellicum Pharmaceuticals Business Overview
Table 100. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product
Table 101. Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 102. Bellicum Pharmaceuticals Recent Developments
Table 103. Mustang Bio Company Details
Table 104. Mustang Bio Business Overview
Table 105. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 106. Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 107. Mustang Bio Recent Developments
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Type: 2023 VS 2030
Figure 3. CAR T-cell Therapy Features
Figure 4. TCR T-cell Therapy Features
Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2023 VS 2030
Figure 7. Acute Lymphocytic Leukemia Case Studies
Figure 8. Chronic Lymphocytic Leukemia Case Studies
Figure 9. B Cell Lymphoma Case Studies
Figure 10. Multiple Myeloma Case Studies
Figure 11. Other Case Studies
Figure 12. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region: 2023 VS 2030
Figure 16. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players in 2023
Figure 17. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2023
Figure 19. North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 21. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 22. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 23. United States Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 26. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 27. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 28. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 29. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 36. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 37. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 38. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 39. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 40. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 41. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2019-2030)
Figure 42. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Taiwan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. India Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 50. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 51. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 52. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Israel Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. GCC Countries Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. Novartis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 59. Kite Pharma Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 60. Juno Therapeutics Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 61. Cellectis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 62. Ziopharm Oncology Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 63. Celyad Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 64. Bluebird Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 65. Bellicum Pharmaceuticals Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 66. Mustang Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of CAR T-cell Therapy
Table 3. Key Players of TCR T-cell Therapy
Table 4. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2019-2024)
Table 8. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2025-2030)
Table 10. Gene Modifying Immunotherapy for Blood Cancer Market Trends
Table 11. Gene Modifying Immunotherapy for Blood Cancer Market Drivers
Table 12. Gene Modifying Immunotherapy for Blood Cancer Market Challenges
Table 13. Gene Modifying Immunotherapy for Blood Cancer Market Restraints
Table 14. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Players (2019-2024)
Table 16. Global Top Gene Modifying Immunotherapy for Blood Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2023)
Table 17. Global Gene Modifying Immunotherapy for Blood Cancer Industry Ranking 2022 VS 2023 VS 2024
Table 18. Global 5 Largest Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Headquarters and Area Served
Table 20. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
Table 21. Global Key Players of Gene Modifying Immunotherapy for Blood Cancer, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2019-2024)
Table 25. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Type (2025-2030)
Table 27. Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2019-2024)
Table 29. Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Application (2025-2030)
Table 31. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 32. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 33. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 34. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 35. North America Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 39. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 40. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 41. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 42. Europe Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 45. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 46. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 47. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 48. China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 49. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 50. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 51. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 52. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 53. Asia Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 54. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 55. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 61. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Gene Modifying Immunotherapy for Blood Cancer Product
Table 66. Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 67. Novartis Recent Developments
Table 68. Kite Pharma Company Details
Table 69. Kite Pharma Business Overview
Table 70. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product
Table 71. Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 72. Kite Pharma Recent Developments
Table 73. Juno Therapeutics Company Details
Table 74. Juno Therapeutics Business Overview
Table 75. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product
Table 76. Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 77. Juno Therapeutics Recent Developments
Table 78. Cellectis Company Details
Table 79. Cellectis Business Overview
Table 80. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product
Table 81. Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 82. Cellectis Recent Developments
Table 83. Ziopharm Oncology Company Details
Table 84. Ziopharm Oncology Business Overview
Table 85. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product
Table 86. Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 87. Ziopharm Oncology Recent Developments
Table 88. Celyad Company Details
Table 89. Celyad Business Overview
Table 90. Celyad Gene Modifying Immunotherapy for Blood Cancer Product
Table 91. Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 92. Celyad Recent Developments
Table 93. Bluebird Bio Company Details
Table 94. Bluebird Bio Business Overview
Table 95. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 96. Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 97. Bluebird Bio Recent Developments
Table 98. Bellicum Pharmaceuticals Company Details
Table 99. Bellicum Pharmaceuticals Business Overview
Table 100. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product
Table 101. Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 102. Bellicum Pharmaceuticals Recent Developments
Table 103. Mustang Bio Company Details
Table 104. Mustang Bio Business Overview
Table 105. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product
Table 106. Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024) & (US$ Million)
Table 107. Mustang Bio Recent Developments
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Type: 2023 VS 2030
Figure 3. CAR T-cell Therapy Features
Figure 4. TCR T-cell Therapy Features
Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2023 VS 2030
Figure 7. Acute Lymphocytic Leukemia Case Studies
Figure 8. Chronic Lymphocytic Leukemia Case Studies
Figure 9. B Cell Lymphoma Case Studies
Figure 10. Multiple Myeloma Case Studies
Figure 11. Other Case Studies
Figure 12. Gene Modifying Immunotherapy for Blood Cancer Report Years Considered
Figure 13. Global Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Gene Modifying Immunotherapy for Blood Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Region: 2023 VS 2030
Figure 16. Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Players in 2023
Figure 17. Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2023
Figure 19. North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 21. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 22. North America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 23. United States Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 26. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 27. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 28. Europe Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 29. Germany Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 36. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 37. China Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 38. Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 39. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 40. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 41. Asia Gene Modifying Immunotherapy for Blood Cancer Market Share by Region (2019-2030)
Figure 42. Japan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Taiwan Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. India Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Australia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Type (2019-2030)
Figure 50. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Application (2019-2030)
Figure 51. Middle East, Africa, and Latin America Gene Modifying Immunotherapy for Blood Cancer Market Share by Country (2019-2030)
Figure 52. Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Israel Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. GCC Countries Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. Novartis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 59. Kite Pharma Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 60. Juno Therapeutics Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 61. Cellectis Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 62. Ziopharm Oncology Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 63. Celyad Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 64. Bluebird Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 65. Bellicum Pharmaceuticals Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 66. Mustang Bio Revenue Growth Rate in Gene Modifying Immunotherapy for Blood Cancer Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Circuit Simulator Market Research Report 2025
Mar 11, 25
Global Schematic Editor Market Research Report 2025
Mar 11, 25
Global Milk Green Tea Market Research Report 2025
Mar 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232